Bone Biologics CORP 10-K annual reports

Bone Biologics Corporation reports recurring operating losses and substantial doubt about its ability to continue as a going concern, despite progress in its spinal fusion clinical study and recent capital raises.

Bone Biologics Corporation reports its financial results for the year ended December 31, 2024, highlighting ongoing clinical trials and financial activities.

Bone Biologics Corporation's 2023 annual report reveals a significant increase in research and development expenses and a net loss, raising concerns about the company's ability to continue as a going concern.